Amino Acid-Based Boron Carriers in Boron Neutron Capture Therapy (BNCT)

Борсодержащие носители на основе аминокислот в борон-нейтронозахватной терапии (БНЗТ)
Jarkko Rautio, Juri M. Timonen, Juulia Järvinen, Herkko Pulkkinen
2023-11-23

boron deliveryboron neutron capture therapyboronated amino acidsboronophenylalanine (BPA)large amino acid transporter 1 (LAT1)
Interest in the design of boronated amino acids has emerged, partly due to the utilization of boronophenylalanine (BPA), one of the two agents employed in clinical Boron Neutron Capture Therapy (BNCT). The boronated amino acids synthesized thus far for BNCT investigations can be classified into two categories based on the source of boron: boronic acids or carboranes. Amino acid-based boron carriers, employed in the context of BNCT treatment, demonstrate significant potential in the treatment of challenging tumors, such as those located in the brain. This review aims to shed light on the developmental journey and challenges encountered over the years in the field of amino acid-based boron delivery compound development. The primary focus centers on the utilization of the large amino acid transporter 1 (LAT1) as a target for boron carriers in BNCT. The development of efficient carriers remains a critical objective, addressing challenges related to tumor specificity, effective boron delivery, and rapid clearance from normal tissue and blood. LAT1 presents an intriguing and promising target for boron delivery, given its numerous characteristics that make it well suited for drug delivery into tumor tissues, particularly in the case of brain tumors.
1
Amino acid-based boron carriers show substantial potential for treating difficult tumors, including brain tumors.
2
Boronated amino acids for BNCT are broadly classified by boron source as boronic-acid or carborane derivatives.
3
Efficient amino acid-based carriers remain an important unmet objective despite progress since BPA development.
4
Key development challenges include tumor specificity, efficient boron delivery, and rapid clearance from normal tissue and blood.
5
The review identifies LAT1 as a promising target for directing boron carriers into tumor tissue, particularly across brain-tumor barriers.

amino acid-based boron carriers for Boron Neutron Capture Therapy (BNCT)

their development and use of large amino acid transporter 1 (LAT1) targeting to achieve tumor-specific boron delivery, effective uptake, and rapid clearance from normal tissues and blood

Publication Details
Publication Date
2023-11-23
Journal
Publisher
ISSN
Cited by
49
Access Type
Author Information
Authors
Jarkko Rautio
Juri M. Timonen
Juulia Järvinen
Herkko Pulkkinen
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%